



EASD

Eye Complications Study Group



25th-27th May 2017

Budapest, Hungary

Danubius Health Spa Resort

Margitsziget****

H-1007 Budapest, Margitsziget

PROGRAMME

ABOUT EASDec

EASDec - EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES

Eye Complications Study Group (EASDec)

EASDec is a Study Group of the European Association for the Study of Diabetes (EASD) with special responsibility for the study of the eye complications of diabetes.

Its aim is to promote the advancement of knowledge of all aspects of diabetic retinopathy, including epidemiology, pathology, pathophysiology, investigation and treatment through active collaboration between ophthalmologists and diabetologists.

The ultimate goal of the Group is to prevent the development of diabetic retinopathy and to search for the best treatment of this condition in people with diabetes.

Meeting Chair

Professor Andrea Facsko, Hungary - President of the Hungarian
Ophthalmological Society

EASDec board members

Scientific Program & Organising Committee

Professor Simon Harding, Liverpool, UK – President

Professor Rafael Simo, Barcelona, Spain – Vice President

Professor Tunde Peto, London, UK – Treasurer

Professor Reinier Schlingemann, Amsterdam, Netherlands – Secretary

Professor Massimo Porta, Turin, Italy – Past President

GENERAL INFORMATION

WEBSITE FOR FURTHER INFORMATION

www.easdec.org

Opening hours of registration

25 May, Thursday	15:00 - 18:30
26 May, Friday	08:00 - 18:00
27 May, Saturday	08:30 - 13:30

Opening hours of the exhibition

25 May, Thursday	16:00 - 18:00
26 May, Friday	09:00 - 18:00
27 May, Saturday	09:00 - 13:00

OFFICIAL LANGUAGE

English

No simultaneous translation will be provided.

LIABILITY

The Local Organising Committee and the Expert-Quality Congress and Travel Agency do not accept liability for personal medical expenses, travel expenses, losses of whatever nature incurred by delegates and/or accompanying persons.

INFORMATION

At the registration desk every staff member will be glad to help you with any enquiries.

LUNCHES

The registration fee does not include lunch for the registered participants on 25th and 27th of May.

REGISTRATION FEES

	Late / On-site fee
Standard	340 €
Resident, Student, Trainee*	240 €
Guest	90 €

*please contact EASDec before registering

Registration fee for regular participants and students includes

- Access to scientific presentations, program book and conference material
- Access to exhibition
- Opening ceremony
- Conference dinner
- Lunch – 26th May, 2017
- Coffee breaks

SILVER SPONSOR



SPONSORS AND EXHIBITORS



IDx Europe B.V.

Retmarker SA

The organisers are grateful for the support of the sponsors and participation of the exhibitors at the congress.

GUIDELINE FOR SPEAKERS

1. Please locate your session room to arrive there at least 20 minutes before the start of the session and deliver the presentation to the technician.
Presentation format: Microsoft PowerPoint, Microsoft Office Windows 10 and Office 2013 program.
Electronic Support: USB only.
Videos should be included in your PowerPoint. Presentation should be in a format that is supported by Windows Media Player.
2. Speakers should keep their presentations to the given time limits and will be asked by session moderators to move to their concluding slide if they overrun.
3. In case of using your own laptop, please inform the team in the Session/ Lecture Room, at least 20 minutes before the start of the session, in order to prepare for this.

INSTRUCTIONS FOR POSTER PREPARATION

Posters must be brought to the Conference by the presenting author and should not be mailed in advance. The required dimensions are 90 cm (width) by 120 cm (height). At the top of the poster, please provide the title, names of the authors and their affiliations, all in bold lettering of about 2.5 to 3 cm size. Artwork and lettering should be large and clear enough so that the poster is readable from a distance of 1.5 m.

The organisers will not accept any responsibility for the collection or delivery / return of posters. Any posters left behind at the end of the meeting will be disposed of by the local organisers.

SOCIAL PROGRAMMES

Opening ceremony 25 May 2017, 18:30

Venue: **Danubius Health Spa Resort Margitsziget******

Included in the registration fee.

Dress code: Smart casual


Conference reception & dinner 26 May 2017, 19:00

Venue: **Europa Boat**

Meet at reception of Danubius Health Spa Resort Margitsziget, Budapest

Included in the registration fee.

Dress code: Smart casual (do bring a jacket as it can be windy on the river)



Congress Organiser

Expert-Quality Congress and
Travel Agency

H-1052 Budapest, Kígyó utca 4-6.

Information: Alexandra Szalma

Tel.: 00 36 1 311 66 87 Fax: 00 36 1 383 79 18

E-mail: congress@eqcongress.hu; Website: www.eqcongress.hu

SCIENTIFIC PROGRAMME

Thursday, 25th May 2017

15:00 Registration

**16:45 SYMPOSIUM
LATE COMPLICATIONS OF DIABETIC EYE DISEASE**

16:45 **Welcome and introductions**

Chaired by: **Associate Professor Tamas Varkonyi and
Professor Andrea Facsko**

17:00 **Associate Professor Tamas Varkonyi, Hungary**

The diabetologist's view: treating diabetes in people with late complications

17:15 **Professor Reinier Schlingemann, Netherlands**

Diabetic macular oedema: treatment paradigms for chronic presentation

17:30 **Associate Professor Miklos Resch, Hungary**

Advanced diabetic retinopathy

17:45 **Professor Zsolt Biro, Hungary**

The diabetic cataract: when to operate?

18:00 Summary and meeting close

The official programme of EASDec starts

18.30-20.00

OPENING CEREMONY with light refreshments and finger food

Opened by **Professors Andrea Facsko and Simon Harding**

Friday, 26th May 2017

08.00 Registration

09.00 INTRODUCTION AND WELCOME

Professor Simon Harding, UK

SESSION 1.

NEW APPROACHES FOR TREATING DIABETIC RETINOPATHY

Chaired by: **Professors Rafael Simo and Jakob Grauslund**

09.15 **Hernández, C (Spain)**

Topical administration of dipeptidyl peptidase iv (DPP-IV) inhibitors prevents retinal neurodegeneration in experimental diabetes

09.30 **Canning, P (Ireland)**

Neuroprotective efficacy of ARA290, an erythropoietin derived peptide, in diabetic retinopathy

09.45 **Beltramo, E (Italy)**

Diabetic-like conditions modulate the expression of thiamine transporters in human retinal cells

10.00 **Hu, TT (Belgium)**

Targeting placental growth factor attenuates retinal permeability and inflammation in diabetic Akimba mice

10.15 **Weksler-Zangen, S (Israel)**

The Cohen diabetic rat an in-vivo model of diabetic retinopathy

10.30 **Vilà-González, M (UK)**

Functional human IPS-ECS from diabetic patients provide a basis for in vitro modelling of diabetic retinopathy

10.45 Coffee/Tea Break

SESSION 2.

NEURODEGENERATION AND BIOMARKERS

Chaired by: **Professor Jose Cunha-Vaz and Dr. Ingeborg Klaassen**

11.25 **Simó, R (Spain)**

Topical administration of somatostatin and brimonidine in the early stages of diabetic retinopathy: results of the Eurocondor study

-
- 11.50 **Costa, M (Portugal)**
Retinal layer location of increased retinal thickness and retinal thinning on the cohort of the Eurocondor clinical trial
- 12.05 **Csutak, A (Hungary)**
Two-years follow up of corneal microstructural changes in patients with Type 1 diabetes mellitus
- 12.20 **Ecsedy, M, E (Hungary)**
Variant SDF1-3'(801)A carriers are an increased risk for diabetic maculopathy
- 12.35 **Cunha-Vaz, J (Portugal)**
Diabetic retinopathy phenotypes of progression to macular oedema. Pooled analysis from independent longitudinal studies of up to two years duration

12.50 Lunch (poster presenters have priority)

SESSION 3. **POSTER SESSION**

13.30-15.30

13.30-14.30 Poster presenters at poster, as moderators will visit

14.30 Tea/coffee served as poster presenters circulate

INVESTIGATION AND IMAGING

Moderated by: **Associate Professor Andrea Csutak and Dr Vivian Schreur**

1. **Blindbæk, S (Denmark)**
Changes in retinal oxygen saturation after intravitreal aflibercept in patients with diabetic macular oedema
2. **Deák, K (Hungary)**
Electrophysiological methods for the detection of subclinical stage retinal and optic nerve involvement in diabetes
3. **Horváth, H (Hungary)**
Choroidal thickness and diabetic retinopathy assessed by swept-source optical coherence tomography in patients with diabetes
4. **Santos, A (Portugal)**
OCT-leakage for quantification and location of fluid in diabetic macular oedema: response to anti-VEGF treatment

5. **Soares, M (Portugal)**
Quantification of retinal microvascular density in diabetic patients using Cirrus Angioplex optical coherence tomography angiography (OCT-A)
6. **Lattanzio, R (Italy)**
Preclinical retinopathy in type 1 diabetes mellitus: screening in paediatric age
7. **Szalay, L (Hungary)**
Early detection of diabetic angiopathy based on the automated analysis of the Optovue RTVue XR 100 Avanti® angio-OCT recordings
8. **Cakir, B (Turkey)**
Corneal epithelial thickness in patients with type 2 diabetes mellitus

LABORATORY SCIENCE

Moderated by: **Professors Cristina Hernandez and Paul Canning**

9. **Klaassen, I (Netherlands)**
Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy
10. **Huang, Y (Taiwan)**
High expression of regulator of cell cycle (RGCC) protein in diabetic retinopathy
11. **Sergeys, J (Belgium)**
Thorough longitudinal in vivo characterisation of the streptozotocin-induced diabetic mouse model
12. **Hajdú, R I (Hungary)**
Detailed evaluation of suspected retinal ganglion cell degeneration in an animal model of type 2 diabetes mellitus

EPIDEMIOLOGY AND RISK FACTORS

Moderated by: **Dr. Amber van der Heijden and Dr. Gabor Toth**

13. **Pék, A (Hungary)**
Cataract and diabetes coexistence based on a RAAB study in Hungary
14. **Tomić, M (Croatia)**
Inflammation and obesity: possible link to the pathogenesis of retinopathy in type 2 but not in type 1 diabetes
15. **Oliveira, C (Portugal)**
RetmarkerDR computed MA formation rate as a predictor of DR progression to diabetic macular oedema. Pooled analysis from different longitudinal studies of up to two years duration

16. **Torp, T (Denmark)**
Changes in retinal arterial geometry in relation to activity of proliferative diabetic retinopathy 6 months after panretinal photocoagulation
17. **Gooding, K (UK)**
Examining longitudinal changes of macular thickness in the early stages of diabetic retinopathy
18. **Blows, P (UK)**
The next steps for the DR-NET: a network to tackle the burden of diabetic retinopathy in 13 low- and middle-income countries

SCREENING AND AUTOMATION

Moderated by: **Professor Frank Verbraak and Dr. Dorottya Szabo**

19. **Antal, B (Hungary)**
Data analysis applied to diabetic retinopathy screening: performance evaluation
20. **Bhaskaranand, M (USA)**
ETDRS 7-field stereoscopic reference standard for clinical validation of automated DR screening on 2-field monoscopic images
21. **D'Souza, Y (UK)**
The diabetic eye screening service goes green in Manchester, UK
22. **Tavakoli, M (UK)**
Implementation of corneal confocal microscopy for screening diabetic neuropathy in primary care: a feasibility and acceptability study
23. **Jones, C (UK)**
Outcomes of referrals from diabetes eye screening to a slit lamp biomicroscopy clinic
24. **Creer, R (UK)**
The introduction of the diabetic passport within ophthalmology clinics at Manchester Royal Eye Hospital: Patient opinion and perceived benefits
25. **Harding, S (UK)**
Safety of individualised variable interval screening for referable diabetic retinopathy – baseline data from the ISDR randomised controlled study
26. **Ramachandra, C (USA)**
Automated longitudinal analysis of retinal fundus images with applications to screening intervals and risk stratification
27. **Ibanez-Bruron, M (UK)**
How well integrated is the ophthalmic care for children and young people living with diabetes in England?

28. **Scanlon, P (UK)**
Diabetic retinopathy screening in China

CLINICAL PRACTICE

Moderated by: **Associate Professor Miklos Resch and Dr Morten B. Hansen**

29. **Lopez Galvez, M (Spain)**
Clinical practice in the management of diabetic macular oedema. Results from a retinologists' national survey
30. **Doğan, E (Turkey)**
Outcomes of repeated intravitreal dexamethasone implant for the treatment of ranibizumab-resistant diabetic macular oedema
31. **Jasani, K (UK)**
A retrospective review of clinical outcomes of intravitreal aflibercept for diabetic macular oedema (DMO) in treatment naïve patients with those switched from alternative therapies over 12 months at Manchester Royal Eye Hospital (MREH)
32. **Ba-Ali, S (Denmark)**
Salivary melatonin concentrations in type-1 and type-2 diabetes mellitus
33. **Peto, T (UK)**
ILUVIEN (fluocinolone acetonide [FAc]) in the management of chronic diabetic macular oedema – assessing the need for additional therapies in clinical practice

SESSION 4

Chaired by: **Professors Simon Harding and Andrea Facsko**

- 15.30 **Gábor Tóth, (Hungary)**
Winner of the best young investigator abstract from Hungary
Diabetes and diabetic retinopathy in people aged 50 and older in Hungary
- 15.45 **Morten B. Hansen (UK)**
Diabetic retinopathy in Europe – results of the E3 Consortium Diabetes Group
- 16:00 **EVA KOHNER LECTURE**
Steve Aldington: "I've looked at life from both sides now"
Introduced by **Professor Simon Harding**

16.45 ANNUAL GENERAL MEETING

Moderator: **Professor Reinier Schlingemann**

19.00 CONFERENCE RECEPTION AND DINNER

Meet at reception of Danubius Health Spa Resort Margitsziget

Saturday 27th May 2016

08.30 Registration

SESSION 5.

EARLY DETECTION AND TECHNOLOGY IN SCREENING

Chaired by: **Professors Tunde Peto and Steve Aldington**

09.00 Verbraak, F (Netherlands)

Real life evidence of improved automated detection of diabetic retinopathy through integration of deep learning

09.15 Van der Heijden, A (Netherlands)

Prediction models for the risk of retinopathy in people with type 2 diabetes. A systematic review

09.30 Stratton, I (UK)

Uptake of diabetic eye screening - are some domains of deprivation more important than others?

09.45 Szabo, D (Hungary)

Telemedical diabetic retinopathy screening in Hungary

10.00 Dupas, B (France)

Decreased macular flow density is associated with visual impairment in patients with florid diabetic retinopathy

10.15 Palarie, N (Moldova)

Role of optical coherence tomography in diabetic macular oedema screening

10.30 Coffee/Tea Break

SESSION 6.

DIABETES INDUCED RETINAL INFLAMMATION

Chaired by: **Professors Reinier Schlingemann and Frank Verbraak**

-
- 11.10 **KEYNOTE LECTURE: Professor Andrea Facsko (Hungary)**
Treating advanced diabetic eye disease
- 11.30 10 minutes discussion
- 11.40 **Tecilazich, F (USA)**
Patroller Monocytes protect retinal microvessels from diabetes
- 11.55 **Solà-Adell, C (Spain)**
Calcium dobesilate prevents the oxidative stress and inflammation induced by diabetes in the retina of db/db mice
- 12.10 **Van der Wijk, A (Netherlands)**
Corticosteroids induce barrier properties of the blood-retinal barrier via direct effects on the endothelium
- 12.25 **Mazzeo, A (Italy)**
Somatostatin protects human retinal pericytes from microglia-mediated inflammation
- 12.40 **Schreur, V (Netherlands)**
The winner of the Professor Anne Katrin Sjolie Prize for the best abstract from a trainee
Hyperreflective foci predict treatment response to bevacizumab in patients with diabetic macular oedema
- 13.00 BEST POSTER PRIZE CEREMONY AND CLOSING REMARKS**
Professor Simon Harding, UK